Comparison of the pharmacokinetic and pharmacodynamic properties of two recombinant granulocyte colony-stimulating factor formulations after single subcutaneous administration to healthy volunteers
Background and objective: The aim of this randomized, single dose, two-period crossover study with two weeks wash-out period was the demonstration of bioequivalence of two recombinant human granulocyte colony-stimulating factor (rG-CSF) formulations after subcutaneous administration of 300 μg compar...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2014-01-01
|
| Series: | Medicina |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1010660X14000500 |
| _version_ | 1827853887769411584 |
|---|---|
| author | Audrius Sveikata Gintautas Gumbrevičius Kastytis Šeštakauskas Rima Kregždytė Vytautas Janulionis Vidmantas Fokas |
| author_facet | Audrius Sveikata Gintautas Gumbrevičius Kastytis Šeštakauskas Rima Kregždytė Vytautas Janulionis Vidmantas Fokas |
| author_sort | Audrius Sveikata |
| collection | DOAJ |
| description | Background and objective: The aim of this randomized, single dose, two-period crossover study with two weeks wash-out period was the demonstration of bioequivalence of two recombinant human granulocyte colony-stimulating factor (rG-CSF) formulations after subcutaneous administration of 300 μg comparing their pharmacokinetic (primary endpoints AUC0–24, AUC0–∞ and Cmax) and pharmacodynamic (primary endpoints ANC AUC0–72, ANC AUC0–∞ and ANCmax) profiles in healthy male subjects.
Materials and methods: A total of 36 (23.0 ± 6.0 years, 76.6 ± 7.2 kg) healthy subjects were recruited. Using a 1:1 randomization ratio, subjects were randomly assigned to one of two possible treatment-sequence groups to receive the single dose of test formulation (Gp-02) and reference product (Neupogen™) concentrations were measured by enzyme-linked immunosorbent assay (ELISA) up to 24 h and the Absolute Neutrophil Count (ANC) was determined using hematology analyzer Coulter STKS™ (Beckman Coulter) up to 72 h after injection. The geometric mean of primary pharmacokinetic and pharmacodynamic variables were considered bioequivalent if the 90% confidence intervals (CI) would fall in the bioequivalence range of 80%–125%.
Results: AUC0–24 (ratio of means 103.4, 90% CI: 95.6–111.9), AUC0–∞ (103.4, 90% CI: 95.7–111.7), Cmax (99.6, 90% CI: 89.0–111.4), ANC AUC0–72 (100.0, 90% CI: 96.6–103.5), ANC AUC0–∞ (100.8, 90% CI: 96.5–105.3), and ANCmax (100.2, 90% CI: 95.4–105.1) were determined. Single doses of test and reference formulations were well tolerated. The incidence of AEs was equally distributed across treatment groups with the most frequent AEs being headache, fever, and back pain.
Conclusions: The study results demonstrated the bioequivalence of Gp-02, a new formulation of filgrastim, and the reference product Neupogen™. |
| first_indexed | 2024-03-12T11:13:18Z |
| format | Article |
| id | doaj.art-2b25ea24dc5f42a0a98d64fbfef949b9 |
| institution | Directory Open Access Journal |
| issn | 1010-660X |
| language | English |
| last_indexed | 2024-03-12T11:13:18Z |
| publishDate | 2014-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Medicina |
| spelling | doaj.art-2b25ea24dc5f42a0a98d64fbfef949b92023-09-02T02:29:34ZengMDPI AGMedicina1010-660X2014-01-0150314414910.1016/j.medici.2014.08.001Comparison of the pharmacokinetic and pharmacodynamic properties of two recombinant granulocyte colony-stimulating factor formulations after single subcutaneous administration to healthy volunteersAudrius Sveikata0Gintautas Gumbrevičius1Kastytis Šeštakauskas2Rima Kregždytė3Vytautas Janulionis4Vidmantas Fokas5Institute of Physiology and Pharmacology, Medicial Academy, Lithuanian University of Health Sciences, Kaunas, LithuaniaInstitute of Physiology and Pharmacology, Medicial Academy, Lithuanian University of Health Sciences, Kaunas, LithuaniaInstitute of Physiology and Pharmacology, Medicial Academy, Lithuanian University of Health Sciences, Kaunas, LithuaniaNeuroscience Institute, Medical Academy, Lithuanian University of Health Sciences, Kaunas, LithuaniaDepartment of Applied Mathematics, Kaunas University of Technology, Kaunas, Lithuania“Biomapas” UAB, Kaunas, LithuaniaBackground and objective: The aim of this randomized, single dose, two-period crossover study with two weeks wash-out period was the demonstration of bioequivalence of two recombinant human granulocyte colony-stimulating factor (rG-CSF) formulations after subcutaneous administration of 300 μg comparing their pharmacokinetic (primary endpoints AUC0–24, AUC0–∞ and Cmax) and pharmacodynamic (primary endpoints ANC AUC0–72, ANC AUC0–∞ and ANCmax) profiles in healthy male subjects. Materials and methods: A total of 36 (23.0 ± 6.0 years, 76.6 ± 7.2 kg) healthy subjects were recruited. Using a 1:1 randomization ratio, subjects were randomly assigned to one of two possible treatment-sequence groups to receive the single dose of test formulation (Gp-02) and reference product (Neupogen™) concentrations were measured by enzyme-linked immunosorbent assay (ELISA) up to 24 h and the Absolute Neutrophil Count (ANC) was determined using hematology analyzer Coulter STKS™ (Beckman Coulter) up to 72 h after injection. The geometric mean of primary pharmacokinetic and pharmacodynamic variables were considered bioequivalent if the 90% confidence intervals (CI) would fall in the bioequivalence range of 80%–125%. Results: AUC0–24 (ratio of means 103.4, 90% CI: 95.6–111.9), AUC0–∞ (103.4, 90% CI: 95.7–111.7), Cmax (99.6, 90% CI: 89.0–111.4), ANC AUC0–72 (100.0, 90% CI: 96.6–103.5), ANC AUC0–∞ (100.8, 90% CI: 96.5–105.3), and ANCmax (100.2, 90% CI: 95.4–105.1) were determined. Single doses of test and reference formulations were well tolerated. The incidence of AEs was equally distributed across treatment groups with the most frequent AEs being headache, fever, and back pain. Conclusions: The study results demonstrated the bioequivalence of Gp-02, a new formulation of filgrastim, and the reference product Neupogen™.http://www.sciencedirect.com/science/article/pii/S1010660X14000500Human granulocyte colony-stimulating factorBiosimilarityPharmacokineticsPharmacodynamicsSafety |
| spellingShingle | Audrius Sveikata Gintautas Gumbrevičius Kastytis Šeštakauskas Rima Kregždytė Vytautas Janulionis Vidmantas Fokas Comparison of the pharmacokinetic and pharmacodynamic properties of two recombinant granulocyte colony-stimulating factor formulations after single subcutaneous administration to healthy volunteers Medicina Human granulocyte colony-stimulating factor Biosimilarity Pharmacokinetics Pharmacodynamics Safety |
| title | Comparison of the pharmacokinetic and pharmacodynamic properties of two recombinant granulocyte colony-stimulating factor formulations after single subcutaneous administration to healthy volunteers |
| title_full | Comparison of the pharmacokinetic and pharmacodynamic properties of two recombinant granulocyte colony-stimulating factor formulations after single subcutaneous administration to healthy volunteers |
| title_fullStr | Comparison of the pharmacokinetic and pharmacodynamic properties of two recombinant granulocyte colony-stimulating factor formulations after single subcutaneous administration to healthy volunteers |
| title_full_unstemmed | Comparison of the pharmacokinetic and pharmacodynamic properties of two recombinant granulocyte colony-stimulating factor formulations after single subcutaneous administration to healthy volunteers |
| title_short | Comparison of the pharmacokinetic and pharmacodynamic properties of two recombinant granulocyte colony-stimulating factor formulations after single subcutaneous administration to healthy volunteers |
| title_sort | comparison of the pharmacokinetic and pharmacodynamic properties of two recombinant granulocyte colony stimulating factor formulations after single subcutaneous administration to healthy volunteers |
| topic | Human granulocyte colony-stimulating factor Biosimilarity Pharmacokinetics Pharmacodynamics Safety |
| url | http://www.sciencedirect.com/science/article/pii/S1010660X14000500 |
| work_keys_str_mv | AT audriussveikata comparisonofthepharmacokineticandpharmacodynamicpropertiesoftworecombinantgranulocytecolonystimulatingfactorformulationsaftersinglesubcutaneousadministrationtohealthyvolunteers AT gintautasgumbrevicius comparisonofthepharmacokineticandpharmacodynamicpropertiesoftworecombinantgranulocytecolonystimulatingfactorformulationsaftersinglesubcutaneousadministrationtohealthyvolunteers AT kastytissestakauskas comparisonofthepharmacokineticandpharmacodynamicpropertiesoftworecombinantgranulocytecolonystimulatingfactorformulationsaftersinglesubcutaneousadministrationtohealthyvolunteers AT rimakregzdyte comparisonofthepharmacokineticandpharmacodynamicpropertiesoftworecombinantgranulocytecolonystimulatingfactorformulationsaftersinglesubcutaneousadministrationtohealthyvolunteers AT vytautasjanulionis comparisonofthepharmacokineticandpharmacodynamicpropertiesoftworecombinantgranulocytecolonystimulatingfactorformulationsaftersinglesubcutaneousadministrationtohealthyvolunteers AT vidmantasfokas comparisonofthepharmacokineticandpharmacodynamicpropertiesoftworecombinantgranulocytecolonystimulatingfactorformulationsaftersinglesubcutaneousadministrationtohealthyvolunteers |